Bausch Health Companies Inc. (BHC) 주식 분석

회사 개요

Bausch Health Companies Inc. operates as a diversified entity within the healthcare sector, specifically focusing on specialty pharmaceuticals and medical devices across gastroenterology, hepatology, neurology, dermatology, and generic pharmaceuticals. The company's business model involves the development, manufacturing, and marketing of products primarily in these therapeutic areas, alongside over-the-counter and aesthetic solutions. As a public entity, the company is categorized under the industry of Drug Manufacturers - Specialty & Generic, reflecting its core activities in producing specialized medicines and medical equipment. The scale of operations is significant, with a total market capitalization of $2.01 billion and an annual revenue of $10.27 billion supported by a workforce of 20,300 employees. These financial figures indicate that while the company generates substantial top-line sales, its market valuation relative to revenue suggests a positioning that relies heavily on cost efficiency and specific product portfolio performance rather than broad market dominance in terms of equity value.

재무 건전성

The company reported a trailing twelve-month revenue of $10.27 billion, with a corresponding net income of $157.00 million and an EBITDA of $3.40 billion. The substantial gap between the $10.27 billion in revenue and the $157.00 million in net income reveals a highly leveraged cost structure where operating expenses, interest, and taxes consume a vast majority of gross profits before reaching the bottom line. Despite the net income figure, the EBITDA of $3.40 billion demonstrates strong underlying cash generation capabilities before financing and non-cash expenses are deducted. The company generated $1.09 billion in free cash flow, which provides a critical buffer for financial flexibility, allowing for potential debt servicing or capital allocation decisions without immediate reliance on external financing. Profitability analysis shows a gross margin of 70.7%, indicating high pricing power or low cost of goods sold in manufacturing, an operating margin of 25.8% reflecting efficient management of overhead costs, and a profit margin of 1.5% that highlights the significant impact of interest expenses and other non-operating costs on the final net income. The balance sheet shows a cash position of $1.31 billion against total debt of $21.08 billion, resulting in a debt-to-equity ratio of 5591.25%, which signifies a highly leveraged position where debt obligations far exceed equity. Although the current ratio stands at 1.47, indicating adequate short-term liquidity to cover current liabilities, the high leverage ratio suggests that the company's solvency is heavily dependent on maintaining consistent cash flows to service its substantial debt load. Return on Equity is calculated at 436.4% and Return on Assets at 5.2%, metrics that require careful interpretation given the high leverage; the elevated ROE is largely a function of the mathematical impact of high debt on equity, while ROA reflects the efficiency of assets in generating income relative to the total asset base.

밸류에이션 평가

The valuation metrics for the stock include a trailing P/E ratio of 12.83 and a forward P/E of 1.34. The drastic difference between the trailing P/E of 12.83 and the forward P/E of 1.34 implies that the market expects a significant increase in earnings per share in the upcoming period, or conversely, that the current earnings are heavily impacted by one-time charges or interest expenses that are expected to normalize. The price-to-book ratio is listed at -3.61, a negative figure that indicates the market values the company at less than its book value, often signaling that the asset base is overstated or that the market anticipates significant impairment charges or restructuring costs. Alternative valuation metrics such as a price-to-sales ratio of 0.20 and an EV/EBITDA of 6.68 suggest that the stock is trading at a discount relative to its sales and enterprise earnings, which can be a result of the high debt load depressing the enterprise value multiples. The stock has traded between a 52-week high of $8.69 and a 52-week low of $4.25, providing a trading range context for investors analyzing volatility. The beta value is 0.40, indicating that the stock price is significantly less volatile than the broader market, moving at roughly 60% of the market's magnitude during periods of fluctuation. This low beta suggests that the stock may serve as a stabilizer in a diversified portfolio, though the negative price-to-book and high debt levels must be weighed against this lower volatility profile.

Growth & Income

Revenue growth over the last year stands at 9.3%, while earnings growth is not available due to the N/A status in the provided data. The availability of a 9.3% revenue increase without a corresponding reported earnings growth figure implies that top-line expansion is outpacing profit realization, likely driven by the high leverage on the income statement where interest and tax expenses prevent net income from keeping pace with sales. Regarding dividends, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm does not currently distribute dividends to shareholders. Instead of paying out earnings, the company reinvests its cash flows, which include the $1.09 billion in free cash flow, into operations, debt reduction, or potential acquisitions to support future growth initiatives. The overall growth and income profile is characterized by strong revenue expansion and significant cash generation, but the absence of a dividend program and high leverage limit the income return component for investors seeking yield.